Use of Chromogenic Peptide Substrates in the Determination of Clotting Factors II, VII, IX and X in Normal Plasma and in Plasma of Patients Treated with Oral Anticoagulants

M.P. van Dieijen-Visser"a,b, J. van Wersch"a, P.J. Brombacher"b, J. Rosing"c, H.C. Hemker"c, G. van Dieijen"c

Departments of aHaematology and bClinical Chemistry, De Wever Hospital, Heerlen, The Netherlands; cDepartment of Biochemistry, University of Limburg, Maastricht, The Netherlands

Key Words. Factors II, VII, IX, X  Chromogenic assays  Monitoring therapy with oral anticoagulants  Thrombotest  Variation in normal values  Therapeutic ranges

Abstract. Spectrophotometric methods were used to assay the clotting factors II, VII, IX and X in plasma of 33 subjectively healthy human donors and in plasma of 98 patients receiving long-term oral anticoagulant therapy. In 33 normal subjects the interindividual variations in the plasma activities of the clotting factors II, VII, IX and X are respectively 12.2, 21.4, 11.0 and 15.0%. After correction for the assay variations the remaining biological variations are respectively 11.7, 21.2, 9.7 and 14.8%.

Plasma from 98 patients receiving long-term anticoagulant therapy was assayed with 'Thrombotest', a clotting test in whole blood introduced by Owren and in these plasmas the activity of each of the vitamin K-dependent factors was assayed with spectrophotometric methods. For the clotting factors IX and VII, novel spectrophotometric methods were applied and the plasma activities thus measured were compared to results obtained with factor IX and VII clotting assays.

Chromogenic activities of the different factors were correlated among each other and with 1/Thrombotest values. When the therapeutic range for Thrombotest values is set between 5 and 12.5% the corresponding therapeutic ranges for the activity of the factors II, VII, IX and X are respectively 12.6–36.1, 27.0–52.3, 23.1–49.3 and 18.9–36.2% (expressed as a percentage of the activity in normal pool plasma). The chromogenic assays for the factors II, VII, IX and X provide the same information on the therapeutic state of the patients in respectively 86.7, 78.6, 81.6 and 89.8% of the cases.

Finally we discuss the suitability of the different assays to monitor oral anticoagulant therapy.
Introduction

For several clotting factors spectrophotometric assays, based on the splitting of specific chromogenic substrates, have been introduced [1-3]. Amidolytic cleavage of such a substrate by an activated clotting factor results in the release of p-nitroaniline which absorbs at 405 nm. Conditions can be chosen such that the change in absorbance at 405 nm is proportional to the concentration of the activated enzyme cleaving the synthetic substrate. The chromogenic substrate S2337 is specific for factor Xa and is used in this study in the chromogenic assays for the factors IX, X and VII. The chromogenic substrate chromozym TH, specific for thrombin, is used in the factor II chromogenic assay.

Synthesis of the clotting factors II, VII, IX and X is vitamin K-dependent and activities of these factors in plasma rapidly diminish when oral anticoagulant drugs are administered. Immediately after the start of oral anticoagulant therapy, plasma activities of the four factors start decreasing with velocities depending on their half-life in plasma. Factor VII disappears most rapidly ($T_{1/2}$, 4–6 h) [4], thereafter factor IX ($T_{1/2}$, 18–30 h) [4, 5]. The half-lives of factors X and II are about 40–60 and 48–96 h, respectively [4-6]. In patients receiving long-term treatment with oral anticoagulants the clotting activities of the four vitamin K-dependent factors are aimed to be kept at 20% of normal [7]. The desired level is dependent on medical considerations [7, 8].

The potential application of a chromogenic substrate method in monitoring antivitamin K treatment has been discussed ever since the introduction of chromogenic substrates in the field of coagulation. The problem of their acceptance is not so much the technical difficulty of devising good spectrophotometric tests but rather the fact that current medical practice has defined therapeutic levels of treatment in terms of overall coagulation tests of the Quick type (e.g. thromboplastin time, Thrombotest) [9]. Now that separate chromogenic tests for the vitamin K-dependent factors are available the problem arises which factor is to be preferred and to which level this factor should be reduced to produce a therapeutic lowering of thrombin-forming capacity, without introducing bleeding risks.

In a large trial ($n = 2,222$), van Wijk [10] observed an acceptable correlation between $1/Thrombotest$ values and factor X chromogenic activity ($r = 0.78$). The therapeutic range for Thrombotest was taken between 5 and 12.5%, the corresponding therapeutic range for factor X chromogenic activity was 180–300 U/l (18–30%) [11]. Poller et al. [12] observed a good agreement between $1/Thrombotest$ and factor VII chromogenic activity in plasma; percentage agreement in diagnosis was 87.5%.

Until now in most experimental studies the chromogenic activity of only one of the vitamin K-dependent clotting factors has been compared to Thrombotest values [10-13] or to the clotting activity of the other vitamin K-dependent factors [10-15]. In the present study the chromogenic activity of all four vitamin K-dependent factors was assayed in healthy human subjects and in patients receiving oral anticoagulant drugs. The chromogenic activities of the vitamin K-dependent factors were correlated both among each other and with $1/Thrombotest$. Based on these results we will discuss the suitability of the different assays to monitor oral anticoagulant therapy.
The Determination of Clotting Factors with Chromogenic Substrates

Materials and Methods

Materials

Venous blood samples were collected in plastic tubes containing as anticoagulant one volume trisodium citrate (0.12 mol/l) per nine volumes of blood. Plasma was prepared by centrifuging the blood samples at 2,000 g for 10 min at room temperature and at 14,000 g for 15 min (4 °C) to obtain platelet-poor plasma. Plasma samples were divided into 5 portions and frozen at −70°C.

Reference pool plasma (normal plasma) was prepared by pooling platelet-poor plasma samples from 40 subjectively healthy subjects (20 men, 20 women). The plasma was frozen at −70°C in small aliquots containing 0.5 ml of the reference pool plasma. During the complete study the same reference pool plasma was used as an internal standard to correct for day-to-day variations.

The chromogenic substrate 52337 (Bz-Ile-Glu (piperidyl)-Gly-Arg-pNA) was obtained from Kabi AB, Stockholm, Sweden. For the factor IX assay one vial (containing 24 mg lyophilized substrate) was dissolved in 12 ml of sterilized distilled water (2.5 mmol/l). For the factor VII and X chromogenic assays one vial was dissolved in 20 ml of sterilized distilled water (1.5 mmol/l).

Albumin chicken egg (ovalbumin) crystallized and lyophilized salt-free grade V, electrophoretic purity 99%. Sigma No. A-5503.

Factor IX-deficient plasma was obtained from a patient with hemophilia B, (factor IX clotting activity < 1%).

Factor VII-deficient plasma was obtained from bovine plasma treated with disisopropyl-phosphorofluoridate (DFP) [16].

Tissue thromboplastin was prepared from human brain as described by Owen [17].

Phospholipids: Brain phosphatidylserine was prepared as described by Sanders [18]. Egg-yolk phosphatidylcholine was obtained from Sigma (No. P8640).

PTT reagent for the factor IX clotting assay was obtained from Roche (Art. No. 0740152). This reagent contains a brain extract serving as a thromboctye substitute and takes care of complete activation of factor XII (Hageman factor) and can be used to measure a decreased activity of the intrinsic system.

Procedures

Thrombotest (Nyegaard & Co., Oslo, Norway) was performed according to Owen [9]. The therapeutic range: 179–192 s, e.g., between 5 and 12.5%. Plasmas from patients who just started therapy or were withdrawn from therapy were excluded from the study.

Proteins: Bovine factor X was prepared according to Fujikawa et al. [19]. The factor X preparations were homogenous and pure as determined by gel electrophoresis in the presence of sodium dodecyl sulfate (SDS). The specific activities of these preparations, as determined with a clotting assay, were equal to those reported by Fujikawa et al. [19].

Bovine contact product was prepared according to Nossel [20] and further purified by heparin-agarose affinity chromatography as suggested by Österud and Rapaport [21]. Contact product was applied to the heparin-agarose column (1.5 × 15 cm) in a buffer containing 0.05 M sodium acetate and 0.3 M NaCl at pH 5.5 eluted with a linear gradient of 0.3–1.0 M NaCl in 0.05 M sodium acetate at pH 5.5.

Phospholipid vesicle preparation: Single bilayer vesicle solutions of a mixture of brain phosphatidylserine and egg-yolk phosphatidylcholine (25/75 w/w) were prepared according to De Kruijf et al. [22] by sonication for 10 min in 50 mM Tris-HCl, 175 mM NaCl at pH 7.9. Sonication was performed using a MSE Mark II 150 W ultrasonic disintegrator set at 10-μm peak-to-peak amplitude. After sonication no pH adjustment was needed.

Spectrophotometric assay for factor II: A test kit commercially available from Boehringer, Mannheim, FRG, was used. In this assay the prothrombin present in a plasma sample is quantitatively converted to thrombin by a complex of factors Xa, Va, phospholipids and calcium. After activation of prothrombin the amount of thrombin present is determined with the chromogenic substrate chromozym TH.

Spectrophotometric assay for factor X: A commercially available test kit was used (Kabi AB, Stockholm, Sweden). In this assay, factor X in a plasma sample is quantitatively converted to factor Xa with the factor X-activating enzyme from Russell’s viper venom. The amount of factor Xa formed is determined with S2337, a chromogenic peptide substrate specific for factor Xa.

Spectrophotometric assay for factor IX: The assay first described by Tans et al. [23] was used. The assay involves the following steps: (1) conversion of plasma factor IX to factor IXa by purified factor Xla (contact product); (2) incubation of factor IXa with factor X, phospholipids and Ca²⁺; (3) addition of EDTA to stop of factor Xa formation by IXa; (4) determination of
factor Xa present from the rate of hydrolysis of S2337; (5) calculation of the amount of factor Xa present, using a calibration curve made with reference pool plasma.

Since the Uvicron 810 (Kontron) spectrophotometer used in our studies is not as sensitive as the Aminco DW2 used by Tantis et al. [23] it was necessary to modify the procedure such that higher absorbance changes were obtained. The details of the method are as follows: in the first step 90 µl buffer with ovalbumin (175 mM NaCl, 50 mM Tris-HCl, pH 7.9 at 25 °C, 0.5 mg/ml ovalbumin), 15 µl CaCl2 (0.1 M), 15 µl (0.225 mg) factor Xla (contact product) and 30 µl plasma (dilution 1:10) incubated at 37 °C during 25 min. From this mixture 100 µl is sampled to a mixture prewarmed at 37 °C for 5 min. containing 200 µl of buffer with ovalbumin, 100 µl factor X (1 µM) and 100 µl Ca²⁺ phospholipid mixture (500 mM phospholipid vesicles and 50 mM Ca²⁺). Factor Xa formation is stopped by transfer of 0.4 ml sample to a cuvette containing 0.55 ml of buffer with ovalbumin, containing 20 mM EDTA.

Finally, 50 µl S2337 (2.5 mM) is added and the change in absorbance at 405 nm is measured. The amount of factor IX in the plasma sample is read from a calibration curve made with varying amounts of the reference pool plasma (fig. 1). A new reference curve was made each time the assay was used in order to correct for day-to-day variations. All measurements were corrected for a reagent blank (ΔA405/min obtained without plasma).

Spectrophotometric assay for factor VII: The procedure first described by Seligsohn et al. [13] was used, modified as follows: in a first step the plasma sample (40 µl, dilution 1:100), containing factor VII, was incubated with tissue thromboplastin (10 µl), CaCl2 0.1 M (20 µl), buffer with ovalbumin, as described for the factor IX assay (110 µl) and a trace of factor Xa (1 nM, 20 µl) to allow quantitative conversion of factor VII to factor VIIa (5 min at 37 °C). Hereafter the factor X activation reaction was started by the addition of factor X (10 µM, 10 µl). After 4 min of factor Xa formation the reaction is stopped by addition of buffer with ovalbumin, containing 20 mM EDTA (0.7 ml). In the last step, factor Xa activity is measured by adding 0.1 ml S2337 (1.5 mM) and determining the initial rate of cleavage of this chromogenic substrate. The amount of factor VII activity was read from a calibration curve of the reference pool plasma. A new calibration curve was made each time the assay was used. Due to the presence of a trace of factor Xa in the preincubation reaction no lag period in the factor Xa formation as reported by Seligsohn et al. [13] was observed. Another difference is that bovine factor X rather than human factor X is used in our assay. The concentration of factor X in the assay is 0.47 µM, equal to three times the plasma factor X concentration. In contrast to the results of Seligsohn et al. [13] with human factor X, we found low blank values in the absence of plasma (reagent blank). The reagent blank was 0.001 ΔA405/min, that is about 1.5 % of the ΔA405/min found for the reference pool plasma (table II). All measurements were corrected for this reagent blank.

Factor VII clotting assay was performed according to Nemerson and Clyne [16].

Factor IX clotting assay: 0.1 ml factor IX-deficient plasma, 0.1 ml test patient plasma (1:10 dilution) and 0.1 ml PTT reagent from Roche were incubated at 37 °C for 5 min. Hereafter 0.025 M Ca²⁺ was added and the clotting time was measured [24].

Statistical analysis of the data: The significance of differences between two values was tested by a paired Student's t test [25]. Rank coefficients of correlation were calculated according to the method of Jonge [25] and Spearman [26]. The rank coefficient of correlation is a distribution-free, nonparametric coefficient of correlation.

Results

Analytical Variables

The linearity of the assays: The linearity of the different chromogenic assays was investigated by testing dilutions of the reference pool plasma and of a patient receiving oral anticoagulant therapy. Figure 1 demonstrates the results for factor IX. Within- and Between-Assay Precision of the different assays is shown in table I. Within-assay precision was estimated by assaying two dilutions of the reference pool plasma (100 and 25 %) 10 times each. Variations are expressed as a percentage of the mean activity in plasma. Between-assay precision of the chromogenic assays was determined by use
The Determination of Clotting Factors with Chromogenic Substrates

Fig. 1. Calibration curve of the factor IX chromogenic assay. Different dilutions of the reference pool plasma (○), Different dilutions of plasma from a patient receiving oral anticoagulants (□).

Table I. Within- and between-assay precision of various assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Within-assay variation, %</th>
<th>Between-assay variation, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100% RP</td>
<td>25% RP</td>
</tr>
<tr>
<td>Factor II chromogenic activity</td>
<td>3.6</td>
<td>5.4</td>
</tr>
<tr>
<td>Factor X chromogenic activity</td>
<td>3.0</td>
<td>4.3</td>
</tr>
<tr>
<td>Factor IX chromogenic activity</td>
<td>5.1</td>
<td>6.7</td>
</tr>
<tr>
<td>Factor IX clotting activity</td>
<td>13.0</td>
<td>6.2</td>
</tr>
<tr>
<td>Factor VII chromogenic activity</td>
<td>3.5</td>
<td>5.6</td>
</tr>
<tr>
<td>Factor VII clotting activity</td>
<td>5.1</td>
<td>3.7</td>
</tr>
<tr>
<td>Thrombotest²</td>
<td>7.4 (40% RP)</td>
<td>3.8 (25% RP)</td>
</tr>
</tbody>
</table>

Coefficient of variation: standard deviation as a percentage of the mean.
Within-assay variation: coefficient of variation for chromogenic measurements on the same day.
Between-assay variation: coefficient of variation for chromogenic measurements on different days.
1 RP = reference pool plasma, obtained from 40 subjectively healthy donors (20 men, 20 women).
2 Thrombotest is insensitive to values larger than 30-40%.
Table II. Variation in normal values

<table>
<thead>
<tr>
<th>Assay</th>
<th>n</th>
<th>Mean % RP</th>
<th>Mean A₄₅₀/₅₃₅</th>
<th>CVₙ</th>
<th>CVₙ₀₁</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor II chromogenic assay</td>
<td>33ᵃ</td>
<td>101.4</td>
<td>0.2468</td>
<td>12.2</td>
<td>11.7</td>
</tr>
<tr>
<td>Factor X chromogenic assay</td>
<td>32ᵇ</td>
<td>106.9</td>
<td>0.162</td>
<td>15.0</td>
<td>14.8</td>
</tr>
<tr>
<td>Factor IX chromogenic assay</td>
<td>33ᵃ</td>
<td>98.2</td>
<td>0.028</td>
<td>11.0</td>
<td>9.7</td>
</tr>
<tr>
<td>Factor IX clotting assay</td>
<td>14ᶜ</td>
<td>94.0</td>
<td>-</td>
<td>16.4</td>
<td>10.0</td>
</tr>
<tr>
<td>Factor VII chromogenic assay</td>
<td>33ᵃ</td>
<td>99.3</td>
<td>0.0645</td>
<td>21.4</td>
<td>21.2</td>
</tr>
<tr>
<td>Factor VII clotting assay</td>
<td>14ᶜ</td>
<td>107.4</td>
<td>-</td>
<td>21.8</td>
<td>21.2</td>
</tr>
</tbody>
</table>

ⁿ = Number of donors; a = 21 men and 12 women; b = 21 men and 11 women, 1 outlier (p < 0.01); c = 7 men and 7 women (RP, see table I).
CVₙ = coefficient of variation expressed as a percentage of mean.

Table III. Mean values for 98 coumarin-treated patients

<table>
<thead>
<tr>
<th>Assay</th>
<th>No assays</th>
<th>Mean % RP</th>
<th>Range % RP</th>
<th>Therapeutic range</th>
<th>% agreement with TT¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor II chromogenic assay</td>
<td>98</td>
<td>29.3</td>
<td>11.3–70.2</td>
<td>12.6–36.1</td>
<td>86.7</td>
</tr>
<tr>
<td>Factor X chromogenic assay</td>
<td>98</td>
<td>31.1</td>
<td>18.5–68.9</td>
<td>18.9–36.2</td>
<td>89.8</td>
</tr>
<tr>
<td>Factor IX chromogenic assay</td>
<td>98</td>
<td>41.7</td>
<td>19.6–96.3</td>
<td>23.1–49.3</td>
<td>81.6</td>
</tr>
<tr>
<td>Factor VII chromogenic assay</td>
<td>98</td>
<td>45.0</td>
<td>15.6–80.3</td>
<td>27.0–52.3</td>
<td>78.6</td>
</tr>
<tr>
<td>Thrombotest</td>
<td>98</td>
<td>10.4</td>
<td>5.0–25.0</td>
<td>5.0–12.5</td>
<td>–</td>
</tr>
</tbody>
</table>

¹ In comparing two different tests, results were divided into three categories: therapeutic, underdosed and overdosed. The percentage agreement between Thrombotest and a chromogenic assay represents the percentage of cases in which the two different tests result in the same diagnosis with relation to oral anticoagulant therapy. (RP, see table I).

Clinical Results

Variation in normal values: We assayed factor II, VII, IX and X chromogenic activities in 33 healthy volunteers (21 men, 12 women). The total variation (interindividual variation) and the biological variation of the normal values are presented in table II. Especially for factor IX a rather small biological variation (less than 10%) is observed. For the factors IX and VII clotting activity was also assayed in 14 normal plasmas (7 men, 7 women). Especially for factor IX a much larger variation in the clotting activity (expressed as a percentage of the same reference pool as used in the chromogenic assay) is observed compared to results obtained with the spectrophotometric method (table II).
The Determination of Clotting Factors with Chromogenic Substrates

Table IV. Correlation between the various chromogenic assays and Thrombotest (TT)

<table>
<thead>
<tr>
<th>Assays</th>
<th>98 coumarin-treated patients¹</th>
<th>101 coumarin-treated patients and 33 normal persons²</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT vs. factor II</td>
<td>0.88</td>
<td>0.83&lt;0.88&lt;0.92</td>
</tr>
<tr>
<td>TT vs. factor X</td>
<td>0.78</td>
<td>0.77&lt;0.84&lt;0.89</td>
</tr>
<tr>
<td>TT vs. factor IX</td>
<td>0.72</td>
<td>0.67&lt;0.78&lt;0.85</td>
</tr>
<tr>
<td>TT vs. factor VII</td>
<td>0.72</td>
<td>0.66&lt;0.76&lt;0.83</td>
</tr>
<tr>
<td>Factor II vs. factor X</td>
<td>0.78</td>
<td>0.76&lt;0.83&lt;0.88</td>
</tr>
<tr>
<td>Factor II vs. factor IX</td>
<td>0.64</td>
<td>0.62&lt;0.73&lt;0.81</td>
</tr>
<tr>
<td>Factor II vs. factor VII</td>
<td>0.65</td>
<td>0.52&lt;0.65&lt;0.75</td>
</tr>
<tr>
<td>Factor IX vs. factor X</td>
<td>0.67</td>
<td>0.74&lt;0.82&lt;0.88</td>
</tr>
<tr>
<td>Factor IX vs. factor VII</td>
<td>0.70</td>
<td>0.58&lt;0.70&lt;0.79</td>
</tr>
<tr>
<td>Factor X vs. factor VII</td>
<td>0.55</td>
<td>0.47&lt;0.61&lt;0.72</td>
</tr>
</tbody>
</table>

rₚ: rank coefficient of correlation, i.e. a distribution free (nonparametric) determination of the coefficient of correlation [cf. 25, 26].

r: coefficient of correlation; the 95% confidence limits are also given.

n = 98: 75 men and 23 women.
n = 134: 98 men and 36 women.

Values in 98 patients on long-term anticoagulant therapy: From the De Wever Hospital in Heerlen we chose 98 patients receiving long-term oral anticoagulant treatment (75 men, 23 women) and compared the Thrombotest values to results obtained with the four different spectrophotometric methods, used to assay the plasma activities of the four vitamin K-dependent factors. Table III summarizes the results and in table IV the coefficients of correlation between the different assays are given. The 95% confidence limits of the coefficients of correlation are shown. We also computed the rank coefficient of correlation, a distribution-free determination of the coefficient of correlation, according to Spearman [26]. This rank coefficient of correlation is not influenced by the range of the measurements. As can be seen from table III, activities of the clotting factors are distributed over different ranges. In this case a rank coefficient of correlation will better reflect the correlation between the different assays, compared to the normal coefficient of correlation.

Figure 2a–d shows the correlation between 1/Thrombotest and the chromogenic activity of the factors II, VII, IX and X. The best correlation was observed between 1/Thrombotest and factor II chromogenic activity (r = 0.88).

The ‘therapeutic range’ is a distinct degree of drug-induced inhibition of the coagulation, which is regarded as protecting against thrombus formation, according to previous clinical experiences the range for the Thrombotest as routinely used in our laboratory is between 179 and 92 s, i.e. between 5 and 12.5%. When the therapeutic range for Thrombotest is set between 5 and 12.5% the
therapeutic ranges for the factors II, VII, IX and X can be calculated (table III).

Comparison of chromogenic assays and clotting assays: For part of the plasma samples, factor VII and factor IX plasma clotting activities were measured with clotting assays and the results were compared to the results obtained with the chromogenic assays. Correlation was good between factor VII chromogenic assay and factor VII clotting assay ($r = 0.94$, fig. 3). However, there was a significant difference between the values obtained for both assays in this group of patients (paired t test, $p < 0.05$). The factor VII clotting activity was consistently lower than the factor VII chromogenic activity. Correlation between factor IX chromogenic activity and factor IX clotting activity was less good ($r = 0.88$, $n = 38$, fig. 4). This is probably caused by the insensitivity of the factor IX clotting assay compared to the factor VII clotting assay. There was no significant difference between the results obtained with the factor IX clotting assay and the results obtained with the factor IX chromogenic assay (fig. 4) ($p < 0.05$).
Discussion

The carboxylation of des-γ-carboxy factors II, VII, IX or X to their biologically active zymogens is vitamin K dependent and thus treatment of patients with vitamin K antagonists will result into decreased levels of the carboxylated forms of the four vitamin K-dependent clotting factors. Thrombin-forming capacity will be decreased under these circumstances and this principle underlies oral anticoagulant therapy for patients with cardiovascular and thromboembolic disorders. At present the routine monitoring of oral anticoagulant therapy occurs with thromboplastin time tests like Thrombotest for example. These clotting assays involve the activation reactions of the extrinsic cascade, resulting in the formation of a fibrin clot. Reduction of the concentration of the vitamin K-dependent clotting factors reduces the rate of some of the activation reactions and the cumulative effects are measured.

Since the introduction of chromogenic peptide substrates for thrombin and factor Xa, spectrophotometric methods have been developed to determine the activity of each of the vitamin K-dependent clotting factors individually. The possible application of chromogenic substrates to monitor oral anti-
Coagulant therapy has been suggested ever since [3, 11-13, 27, 28]. One of the advantages of the use of chromogenic substrates to monitor oral anticoagulant therapy is that spectrophotometric methods can be automated, resulting in considerably smaller assay variations. When the automated analyzer is interfaced with a computer the results for a test sample can be translated into a dosage by a computer-programmed dosage scheme [11].

Presently a much discussed question is which of the vitamin K-dependent factors should be chosen to monitor oral anticoagulant therapy. Before there can be thought of replacing Thrombotest by a spectrophotometric assay it has to be evaluated very carefully which of the four factors, if any, should be preferred.

In table V we give several criteria that can be used to evaluate the suitability of the different chromogenic tests to monitor oral anticoagulant therapy: (1) The assay used should be simple; (2) The biological variation in the normal plasma activity should be small; (3) The biological halflife of the clotting factor should be short, because plasma activities of clotting factors that have a short halflife better reflect the momentary state of anticoagulation of the patient; (4) It should be possible to define a zone of optimal anticoagulation. Up till now this has been defined in
terms of Thrombotest values. This, however, is an overall test and it is actually unknown which factor(s) is (are) responsible for therapeutic effects and bleeding risk. Therefore, finally a large prospective double-blind study to compare the results obtained with the best chromogenic assay and the conventional Thrombotest should be performed.

**Assay Variation and Simplicity of the assay**

The chromogenic assays for factors II and X involve only a few pipetting steps and can be completed within 5 min. In contrast the assay for factor IX in its present form requires long incubation times. Further research could lead to simplification of this assay. Inclusion of factor VIIIa in the assay would shorten the assay time, because it stimulates the rate of factor X activation and therefore measurable amounts of factor Xa would be produced faster. The larger assay variation for factor IX (table I), compared to assay variations of 3–3.5% for the factors II, VII and X may be a consequence of the fact that the factor IX assay requires longer incubation times and produces smaller absorbance changes than the other assays. Automation of the assay could reduce this variation. Automation of the factor X assay reduced the assay variation from 3.5 to 1.9% [10].
Fig. 3. Correlation between factor IX clotting assay and factor IX chromogenic assay for factor IX activity in healthy subjects (n = 14) and in patients receiving oral anticoagulants (n = 24).

Table V. Criteria to evaluate the suitability of different chromogenic assays to monitor oral anticoagulant therapy

<table>
<thead>
<tr>
<th>Assay</th>
<th>Assay variation, %</th>
<th>Simplicity of the assay</th>
<th>Biological half-life, h</th>
<th>Biological variation, %</th>
<th>Relation to TT, r₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor II chromogenic assay</td>
<td>3.6</td>
<td>2</td>
<td>48-96</td>
<td>11.7</td>
<td>0.88</td>
</tr>
<tr>
<td>Factor X chromogenic assay</td>
<td>3.0</td>
<td>3</td>
<td>40-60</td>
<td>14.8</td>
<td>0.78</td>
</tr>
<tr>
<td>Factor IX chromogenic assay</td>
<td>5.1</td>
<td>5</td>
<td>18-30</td>
<td>9.7</td>
<td>0.72</td>
</tr>
<tr>
<td>Factor VII chromogenic assay</td>
<td>3.5</td>
<td>4</td>
<td>4-6</td>
<td>21.2</td>
<td>0.72</td>
</tr>
<tr>
<td>Thrombotest</td>
<td>3.8</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Ideal assay: one-step; small assay variation; short biological half-life; small biological variation.

1 Simplicity of the assays is graded on a scale from 1 to 5, where 1 can be carried out fast in a few steps, whereas 5 is a more complicated and time-consuming assay.
An advantage of Thrombotest remains that it can be carried out in whole blood whereas plasma is needed in the chromogenic assays. Therefore, Thrombotest is especially suitable in urgent situations, since one test can be performed within 2 min. Although clotting assays can be mechanized, which requires special apparatus, chromogenic assays can be implemented on automated spectrophotometers already present in the clinical laboratory.

Biological Variation

The biological variations in the activity in plasma of the factors X and VII, measured with chromogenic assays and estimated from the activity in plasma of 33 healthy subjects, show great similarities with results obtained by van Wijk et al. [11] for factor X and by Seligsohn et al. [13] for factor VII. The activity of the factors II and IX in 'normal' plasma, measured with a chromogenic assay are published here for the first time. For factor IX the smallest biological variation is found (less than 10%) and the largest biological variation is found for factor VII (about 22%). Choice of a factor (like IX) with a small biological variation is preferable since a reduction in activity of that factor (as a result of anticoagulant therapy), more accurately reflects a change in synthesis rate.
Biological Half-Life

Due to the short half-life of disappearance of factor VII (as measured after the administration of a blocking dose of anticoagulant) and of reappearance (as measured after the subsequent administration of vitamin K) factor VII levels in plasma are the first to be lowered after beginning of anticoagulant therapy. However, the large biological variation of factor VII activity in plasma makes this factor less suitable to monitor patients receiving oral anticoagulants. Therefore, factor IX with a half-life somewhat larger than factor VII should be preferred because it also has the lowest biological variation (<10%). Moreover, on the general principle that the frequency at which the patients should be controlled must be of the order of magnitude of the half-life of the phenomenon to be observed, factor VII can be excluded as a suitable candidate to monitor oral anticoagulant therapy. According to this principle, factors II and X are not suitable to monitor patients receiving oral anticoagulants for only a short period of time [Hemker and van Dam-Mieras, unpublished results]. The coefficient of correlation that we found between the reciprocal of Thrombotest and factor X chromogenic activity is comparable with that reported by Bergström and Egberg [28] and by van Wijk et al. [11]. The therapeutic range for Thrombotest also compares well with the results obtained by van Wijk et al. [11].

Poller et al. [12] observed a percentage agreement in diagnosis, assessed with Thrombotest and factor VII chromogenic activity of 87.5% in patients receiving long-term anticoagulant therapy.

Treatment with vitamin K antagonists results in the appearance of partly carboxylated factor II, VII, IX and X molecules in the circulation. Partly carboxylated molecules may account for the significant differences in plasma activities measured with a clotting assay or with a chromogenic assay, as observed for factor X by van Wijk et al. [11], and for factor VII by Seligsohn et al. [13] and in this study. However, the difference we observed between factor VII clotting activity and factor VII chromogenic activity is much less than that observed by Seligsohn et al. [13]. For factor IX we found no significant difference between activities measured with a clotting test or with a chromogenic assay.

We conclude that factor II but also the factor X chromogenic activity in plasma can be used to monitor patients receiving long-term anticoagulant therapy, whereas factor IX chromogenic activity should be preferred to monitor patients receiving oral anticoagulants during a short period of time.

Acknowledgements

We thank Truus Janssen-Claessen for the preparation of factor X, contact product and tissue factor and for performing the factor VII clotting measurements.

References

5. Loeliger, E.A.; Hensen, A.: Substitution therapy in
The Determination of Clotting Factors with Chromogenic Substrates

255


Received: March 12, 1982
Accepted in revised form by Editor J.C.W. van de Loo: April 27, 1982

M.P. van Diejen-Visser,
Department of Clinical Chemistry,
De Wever Hospital, PO Box 4446,
NL-6401 CX Heerlen (The Netherlands)